- In June 2025, Daesang's global kimchi brand Jongga unveiled a gourmet kimchi line in the U.S. through a collaboration with Michelin 3-star chef Corey Lee. Named San Ho Won Kimchi, the line features two premium varieties that blend Jongga’s 38 years of fermentation expertise with Chef Lee’s culinary artistry. This partnership highlights kimchi’s evolving role in global cuisine, offering bold, refined flavors. As kimchi undergoes fermentation, it can also become a source of vitamin K2 (menaquinone), a nutrient produced by certain bacteria during the process
- In March 2025, SunWay Biotech and Gnosis by Lesaffre announced a strategic partnership to launch MenaQ7® Metabolic, their first joint product targeting the global vitamin K2 market. This innovative formulation combines MenaQ7® Vitamin K2 as MK-7, known for its clinically proven benefits for bone and heart health, with ANKASCIN® 568-R, a red yeast rice fermentation ingredient uniquely free of Monacolin K (statin). The collaboration aims to deliver high-quality, science-backed nutraceutical ingredients to meet growing global demand and support metabolic health through advanced fermentation technologies
- In October 2023, Smidge® Small Batch Supplements introduced a new premium product: grass-fed Australian Emu Oil softgels. Sustainably sourced from heritage-bred emus in Southeast Australia, this small-batch supplement delivers vitamin K2 (MK-4) in its most bioavailable form. Each serving contains 1,500 mg of pure emu oil, including 6.4 mcg of vitamin K2, along with naturally occurring omega fatty acids. The oil is gently rendered at low temperatures to preserve its nutritional integrity, supporting collagen production, as well as skin, bone, and dental health
- In November 2023, Abbott introduced a new formulation of PediaSure featuring its proprietary Nutri-Pull System—a blend of vitamin K2, vitamin D, vitamin C, and casein phosphopeptides (CPPs). This innovative system is designed to enhance nutrient absorption and support catch-up growth in children, particularly those facing nutritional gaps. By improving the bioavailability of essential nutrients, the product aims to address undernutrition and promote healthy development during critical growth phases
- In June 2022, Balchem Corporation signed a definitive agreement to acquire Kappa Bioscience AS, a Norwegian manufacturer renowned for its science-based vitamin K2 (MK-7) solutions. The deal, valued at approximately USD 338 million, was finalized later that month. This strategic acquisition enhances Balchem’s footprint in the human nutrition and health sector by integrating Kappa’s flagship K2VITAL® brand—recognized for its purity, stability, and clinical backing—into its portfolio. The move also expands Balchem’s global reach and research capabilities, reinforcing its commitment to delivering high-quality, specialty nutrients
